In agreement with this view, a TET1 isoform that lacks regulatory domains, including its DNA-binding domain, but retains its catalytic activity, is enriched in cancer cells (Good et al., 2017), suggesting that mistargeted TET activity may drive oncogenic events, such as genomic instability. Here, TET1 is linked to cancer.